Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dramatic shifts in demand, capacity, and site of service have impacted total hip arthroplasty (THA) volumes and revenues over the 2019-2021 time period. Moving THA off the inpatient-only (IPO) list for Centers of Medicaid and Medicare Services (CMS) beneficiaries and the COVID-19 pandemic [1] has caused a shift in delivery away from inpatient services and a decrease in demand. This study is an analysis of CMS THA metrics during this difficult period for delivering elective orthopedic surgery.

Both the COVID-19 pandemic and the elimination of THA from the IPO list have greatly accelerated the implementation of outpatient THA in the CMS population. As the Delta variant surge has peaked and Omicron has emerged, new challenges for hospitals have persisted and will continue with staffing shortages in nursing, perioperative personnel, and support staff resulting in scheduling challenges for THA surgeons in hospitals. This has caused a movement toward ambulatory surgery center utilization of both THA volume and operating room support staff seeking a more predictable lifestyle and higher wages. Physician

There was no funding received for this work.

No IRB approval was necessary for this work. There is no deidentified patient data in this analysis. This is a data base research project.

One or more of the authors of this paper have disclosed potential or pertinent conflicts of interest, which may include receipt of payment, either direct or indirect, institutional support, or association with an entity in the biomedical field which may be perceived to have potential conflict of interest with this work. For full disclosure statements refer to https://doi.org/10.1016/j.arth.2022.02.101.

* Address correspondence to: Richard Iorio, MD, Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Boston, MA 02115.

https://doi.org/10.1016/j.arth.2022.02.101

0883-5403/© 2022 Elsevier Inc. All rights reserved.
shortages in primary care, anesthesia, and surgical services have caused access problems both in primary care and in THA surgical care [2,3]. The aim of the current study is to assess the removal of THA from CMS’s IPO list and the simultaneous effect of the COVID-19 pandemic on THA demand, CMS finances, and delivery care pathway metrics, resulting in the rapid shift away from inpatient THA.

**Methods**

Medicare claims data were surveyed for the latest period available (April 1, 2020 to September 30, 2020) and compared with a similar period in 2019 before THA came off of the IPO list and before the COVID-19 pandemic impacted the US healthcare system. Length of stay (LOS), admission status, site of service, discharge status, cost to CMS, and racial disparities were analyzed. Volume differences in THA intervention for fracture vs non-fracture patients were also analyzed.

We used 100% Centers for Medicare and Medicaid Service (CMS) fee-for-service inpatient and outpatient claims data, and Medicare enrollment data spanning 2019-2020. We identified April 2020 as the first full month after the onset of the COVID-19 pandemic, and therefore set April 1, 2020 as the start date for the COVID-19 period. Since at the time of our analysis, the claims data extended through December 31, 2020, we examined cases admitted by December 18 to ensure we could capture the full LOS. We examined the same time period of cases (April 1 to December 18 admissions) in 2019 as in 2020 to ensure comparability between the years. The study included primary THAs (and total knee arthroplasty [TKA] to calculate a comparison for all total joint arthroplasty [TJA] admissions) that were coded as inpatient using diagnosis-related group 469 and 470, and outpatient using primary Current Procedural

**Table 1**

|                       | COVID-19  | Aggregate |
|-----------------------|-----------|-----------|
|                       | January/February 2020 | April 2020 | Change (%) | 2019 | 2020 | Change (%) |
| All hospitalization (sum of below) | 0.80   | 0.12 | –85% | 6.58 | 5.00 | –24% |
| White                  | 0.91   | 0.14 | –84% | 7.44 | 5.74 | –23% |
| Non-White              | 0.38   | 0.05 | –88% | 3.36 | 2.30 | –31% |
| Types of hospitalization |       |       |       |       |       |       |
| Primary TKA            | 0.45   | 0.01 | –97% | 3.55 | 2.45 | –31% |
| White                  | 0.51   | 0.01 | –97% | 3.97 | 2.78 | –30% |
| Non-White              | 0.22   | 0.01 | –97% | 1.99 | 1.23 | –38% |
| Primary TKA non-fracture | 0.26   | 0.02 | –94% | 2.26 | 1.85 | –18% |
| White                  | 0.10   | 0.01 | –95% | 0.93 | 0.70 | –25% |
| Non-White              | 0.08   | 0.08 | –7%  | 0.75 | 0.70 | –7%  |
| Primary TKA fracture   | 0.10   | 0.09 | –6%  | 0.88 | 0.83 | –6%  |
| White                  | 0.03   | 0.03 | –20% | 0.28 | 0.25 | –8%  |
| Non-White              | 0.03   | 0.01 | –55% | 0.30 | 0.25 | –17% |
| Revision               | 0.04   | 0.02 | –55% | 0.34 | 0.28 | –16% |
| White                  | 0.02   | 0.01 | –60% | 0.17 | 0.13 | –25% |
| Non-White              |         |       |       |       |       |       |

TKA, total knee arthroplasty.

*Fig. 1. Weekly average hospitalization volume per 1,000 medicare beneficiaries for primary THA non-fracture. THA, total hip arthroplasty.*
Terminology code 27130 for THAs (and 27447 for TKAs for TJA calculation). The study also included revision of THA using diagnosis-related group 466 and 467 for inpatient, and Current Procedural Terminology codes 27134, 27137, and 27138 for outpatient hip revisions.

Within the inpatient setting, we identified hip procedures through each case’s primary International Classification of Diseases 10th Revision Procedure (ICD-10-PCS) codes. We also identified if a case involved a hip fracture through its primary ICD-10 diagnosis codes. We then divided our data into the following groups: primary THAs, primary non-fracture THAs, primary fracture THAs, and revision THAs.

We defined race and ethnicity using the race variable from the Medicare beneficiary enrollment data. Race and ethnicities include White, Black, Hispanic, Asian, other, and unknown. We grouped minorities including Black, Hispanic, Asian, and other into the non-White racial group to compare with the White racial group.

For outcome metrics, we examined the total case volume, index hospitalization (hospitalization where the arthroplasty occurred) LOSs, percentage of cases discharged home post arthroplasty, percentage of cases readmitted within 30 days after the index hospitalization, percentage of cases coded as outpatient, percentage of cases with same-day discharge (SDD), and average reimbursement per case for physicians. We compared the changes in these metrics between 2019 and 2020.

**Results**

From 2019 to 2020, the following changes in primary THA metrics occurred (overall change in TJA [THA plus TKA] metrics). CMS THA volume decreased from 78,691 to 65,360 which resulted in a 16% decrease with a 22% decrease in TJA volume. THA performed as an outpatient increased from 0% to 51% after the index hospitalization, percentage of cases coded as outpatient, percentage of cases with same-day discharge (SDD), and average reimbursement per case for physicians. We compared the changes in these metrics between 2019 and 2020.

Los and an 11% reduction in overall TJA LOS. Inpatient LOS increased from 1.92 to 2.05 days which was a 7% increase in THA LOS and a 16% increase in TJA inpatient LOS. Outpatient LOS increased from 0.92 to 0.93 days which resulted in a 1% increase in outpatient THA LOS and a 12% decrease in overall TJA outpatient LOS. Racial disparities in primary and revision THA intervention rates were similar to pre-pandemic levels and continued during the pandemic (Figs. 2 and 3). There were no racial disparities for THA fracture intervention rates pre or post pandemic (Fig. 4). Revision THA intervention rates followed the same pattern of decline as primary THA rates during the COVID-19 pandemic (Fig. 3).

Discharge home increased from 82% to 91% of CMS beneficiaries with a 12.8% increase for THA patients and an 11% increase for all TJA patients. CMS spending decreased from $1,033 million to $751 million, with a decrease of 27% for THA and an overall 27% decrease for TJA (Fig. 5). This decrease in overall CMS outlay for THA specifically and TJA in general was a combined result of decreased episode reimbursement due to the IPO rule regulatory hospital reimbursement changes, the decrease in surgeon reimbursement due to Relative Value Unit (RVU) Update Committee changes in surgeon reimbursement, and volume decreases in intervention due to the COVID-19 pandemic [4].

**Discussion**

Medicare payments dramatically declined from 2019 to 2020. LOS decreases and shift to outpatient designations were accelerated by IPO list changes and COVID-19 issues. The percentage of SDD cases also increased. Other metrics favorable to decreased spending by CMS were increased discharge to home and decreased volume. Decreased surgeon and hospital reimbursement due to the IPO rule and Relative Value Scale Update Committee regulatory changes also contributed to the decrease in cost to CMS. THA metrics were affected by race.

There are many unintended consequences to the IPO rule application and Relative Value Scale Update Committee regulatory changes. Reduced reimbursement for hospitals and surgeons raises...
Fig. 3. Weekly average hospitalization volume per 1,000 medicare beneficiaries for revision THA non-fracture. THA, total hip arthroplasty.

Fig. 4. Weekly average hospitalization volume per 1,000 medicare beneficiaries for primary THA due to fracture with and without race. THA, total hip arthroplasty.
questions about sustainability of private practice, hospital employment, and the access to care for TJA patients [4]. For 2022, CMS proposes a Physician Fee Schedule conversion factor of $33.58, which is a $1.31 decrease from the 2021 conversion factor of $34.89, to reflect the proposed budget neutrality adjustment that accounts for changes in RVUs and the expiration of the one-time 3.75% payment increase Congress provided through the Consolidated Appropriations Act in 2021. This will result in a 3.4% payment reduction in 2022 due to the conversion factor changes and CMS’ decision to reduce wRVUs associated with TJA. A 6% Medicare surgeon reimbursement cut has been delayed until 2023. In addition, the current inflationary environment projected at >5% in which we currently practice will increase the impact of these cuts. Over the next 3 years the combined effect of these reductions may amount to a >15% reduction in surgeon reimbursement [4].

The limitations of this study are consistent with all database studies and the data are only as accurate as the reporting agency which bears responsibility for collection. Quality metrics and economic data only reflect fee-for-service Medicare beneficiaries and not Managed Medicare, Medicare Advantage, or Dual Eligible Medicare patients. Additionally, changes in TJA surgical volume may have been influenced by changes in access to care, COVID-19 restrictions, staffing reductions, site of service questions related to the IPO rule, and hospital TJA service line issues related to reduced margins. It remains to be seen which of these issues will persist or be rectified in the future. Hospital consolidation, hospital employment of surgeons, the challenges of private practice in a decreasing reimbursement environment, and the limitation of access of some patients to Ambulatory Surgery Centers (ASCs) are problems which cannot be analyzed in this data set and have profound influence over the future of THA care.

The COVID-19 pandemic has accelerated the move to SDD and hospital outpatient department TJA and the use of ASCs for TJA [5]. Now that Medicare has removed both THA (2018) and TKA (2020) from the IPO list, these procedures for Medicare recipients can take place in free-standing ASCs [6]. The surgeon and patient remain the best judges of the appropriate site of care for patients in a shared decision-making model. The unintended impact of the IPO rule and decreased volume associated with the COVID-19 pandemic has unfairly affected the surgeon’s ability to generate revenue and to provide care to Medicare beneficiaries. These changes may lead to unforeseen future access barriers for arthroplasty care.

References

[1] Ellsein J. Covid-19 deaths reported in the U.S. as of November 3, 2021, by age. Health Pharma Medtech State Health. Stat 2021;5.
[2] Lagasse J. Covid-19 recovery is hampered by mounting physician shortages, AAMC finds. https://Healthcarefinancenews.com [accessed 21.06.21].
[3] Iorio R, Peavy PR, Keyes D, Dempsey S, McCreary DO, Kang JD. Improving arthroplasty efficiency and Quality through Concentrating service volume by Complexity: Surviving the Medicare Policy changes. J Arthroplasty 2021;36: 3055−9. https://doi.org/10.1016/j.arth.2021.04.005. Published online.
[4] Skeehan CD, Ortiz D, Sicat CS, Iorio R, Slover J, Bosco J. The 2021 CMS Fee Schedule’s impact on Adult Reconstruction surgeon Productivity and reimbursement. J Arthroplasty 2021;36:3381−7. https://doi.org/10.1016/j.arth.2021.06.004.
[5] Anoushiravani AA, O’Connor CM, DiCaprio MR, Iorio R. Economic impacts of the COVID-19 Crisis: an orthopaedic Perspective. J Bone Joint Surg Am 2020;102: 937−42. https://doi.org/10.2106/JBJS.20.00557.
[6] Anoushiravani AA, Barnes CL, Bosco JA, Rozic KJ, Huddleston JJ, Kang JD, et al. Reemergence of Multispecialty inpatient elective orthopaedic surgery during the COVID-19 pandemic: Guidelines for a new Normal. J Bone Jt Surg Am 2020;102:e79.1−8. https://doi.org/10.2106/JBJS.20.00829.